For the evaluation of anti-Nectin-2 antibodies in in vitro assays and in vivo studies, we selected OV-90 ovarian cancer cells, which highly expressed Nectin-2 with a median fluorescent intensity (MFI) of 242 in FCM, and MDA-MB-231 breast cancer cells (MFI = 181). This evidence concerns the gene NECTIN2 and breast carcinoma.